Employees: 1,805
Size Standard Chemical & Pharmaceutical (1720.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $329M, the 601st largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$55.30 on 18 Nov 2026.
Performance Over six months the shares fell 1.2%, against -20.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 4.6% over the last twelve months (peer median +2.7%); the operating margin is 21.9% (peer median -1.9%).
Valuation It trades at 1.8× enterprise value to sales against a peer median of 3.3× (5th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -12% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -22 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.9 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$7.23B | NT$7.02B | NT$6.79B | NT$6.24B | NT$5.85B |
| Revenue growth | — | +3% | +9% | +7% | — |
| Gross profit | NT$3.05B | NT$2.80B | NT$2.89B | NT$2.65B | NT$2.42B |
| EBITDA | NT$2.03B | NT$1.80B | NT$1.80B | NT$1.61B | NT$1.42B |
| Net income | NT$1.00B | NT$928M | NT$881M | NT$835M | NT$815M |
| Free cash flow | NT$1.23B | NT$1.38B | NT$1.07B | NT$760M | -NT$48.5M |
| Capital expenditure | NT$495M | NT$508M | NT$609M | NT$634M | NT$1.20B |
| Total debt | NT$970M | NT$1.13B | NT$921M | NT$1.70B | NT$2.25B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1720.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | -6.0% | 11th highest of 21 |
| 6-month return | -1.2% | -20.4% | 7th highest of 21 |
| Distance from 52-week high | -8.7% | -36.4% | 3rd highest of 21 |
| Revenue growth (TTM) | +4.6% | +2.7% | 9th highest of 20 |
| Operating margin | 21.9% | -1.9% | 3rd highest of 19 |
| EV / Sales | 1.8× | 3.3× | 5th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -11.5% | 14.0% | 2nd least demanding of 12 |
| Growth delivered (Del g) | +10.3% | +3.1% | 3rd highest of 12 |
| Hurdle (Req g minus delivered) | -21.8 pp | +17.6 pp | 3rd least demanding of 12 |
| ROIC minus cost of capital | +6.9 pp | -7.7 pp | 2nd highest of 18 |
| EV / EBITDA | 6.3× | 15.8× | 2nd cheapest of 7 |
| Net debt / EBITDA | -0.6× | -1.8× | 4th most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | 1.8× | -11.5% | +10.3% |
| Chongqing Hifuture Information Technology 002168.SZ | China | $326M | -27% | +2% | -6% | 7.4× | 14.3% | -14.0% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | 1.4× | 9.2% | +6.5% |
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | 1.2× | 19.0% | -0.9% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $326M | -39% | +10% | -8% | 6.2× | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 4.8× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $334M | +12% | +27% | 8% | 2.4× | 38.3% | -3.2% |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $322M | -12% | +6% | -104% | 21.4× | n/a | n/a |
| Swedencare SECARE.ST | Sweden | $321M | -24% | +3% | 7% | 1.8× | 6.1% | +62.1% |
| GC Corp. 005250.KS | South Korea | $321M | -45% | +2% | 3% | 1.1× | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $320M | -5% | n/a | n/a | n/a | n/a | n/a |
| Kitazato 368A.T | Japan | $317M | +7% | +9% | 52% | 3.1× | -16.8% | +5.4% |
| Inovio Pharmaceuticals INO | United States | $317M | +37% | +64% | -25,954% | 921.6× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $314M | +150% | +66% | 9% | 3.4× | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $312M | -20% | -36% | -57% | 5.6× | 27.5% | -6.4% |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | 1.9× | 8.0% | -11.3% |
| Alembic ALEMBICLTD.NS | India | $309M | +25% | -5% | 26% | 13.0× | 44.3% | +26.7% |
| Enwei Pharmaceutical 301331.SZ | China | $308M | -20% | -7% | 5% | 2.1× | 14.0% | +7.3% |
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | n/a | n/a | n/a |
| Hinova Pharmaceuticals 688302.SS | China | $305M | -35% | +251% | -195% | 17.1× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | 1.1× | 3.6% | +3.1% |